Glenmark Enters into a Collaboration Agreement with Jiangsu and 3D Medicines to Develop Envafolimab (KN035) for the Treatment of Cancer Indications
Shots:
- Glenmark Specialty signed a license agreement with Jiangsu & 3D Medicine for an exclusive license to develop, register & commercialize Envafolimab for the treatment of Oncology indications across India, Asia Pacific, the Middle East, Africa, Russia, CIS & Latin America
- As per the agreement, Jiangsu, on behalf of both the Licensors, will receive a low double-digit payment up to launch, additional triple-digit milestone payments plus a royalty fee of single-to-double-digit percentage
- Envafolimab is a recombinant single-domain antibody against PD-L1 fused with human Fc. Earlier, in Nov 2021, Envafolimab was approved by the NMPA as Enweida for advanced solid tumors whereas in the USA it is being developed by Tracon Pharma
Ref: Glenmark | Image: Glenmark
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Shivani was a content writer at PharmaShots. She has a keen interest in recent innovations in the life sciences industry. She was covering news related to Product approvals, clinical trial results, and updates. We can be contacted at connect@pharmashots.com.
